Synthetic cannabinoids produce their main effects through CB1 receptors, just like THC, according to quantitative pharmacological analysis

In vivo pharmacological analysis in mice using the cannabinoid triad (catalepsy, antinociception, hypothermia). The CB1 antagonist rimonabant was used to generate rightward shifts in dose-response curves for each compound. pA2 and pKB values were calculated to estimate apparent CB1 receptor affinity.

Understanding whether synthetic cannabinoids work through CB1 or other targets has implications for both treatment and regulation. This study shows that their core effects are CB1-mediated, meaning their increased danger likely comes from higher potency and efficacy at CB1, not from activating different receptors.

If synthetic cannabinoids worked through non-CB1 targets, they would require different clinical management than THC intoxication. The confirmation that CB1 mediates their core effects means that CB1-based approaches to treating overdose or adverse reactions should be applicable to synthetic cannabinoid emergencies as well.

Only tested three pharmacological endpoints (the classic triad). Synthetic cannabinoids may have non-CB1 effects on other systems (e.g., seizures, psychosis) not captured by this analysis. The analysis focuses on central effects; peripheral effects may involve other targets. Only five of the many synthetic cannabinoids in circulation were tested.